Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

Psilocybin Mushrooms Just Beginning to Create Sizable Buzz with Investors

Livemoney May 14, 2020

MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator

Canada NewsWire May 11, 2020

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire May 11, 2020

MindMed Announces Increase in Bought Deal Offering to Approximately $11.5 Million

GlobeNewswire May 6, 2020

MindMed Announces $10 Million Bought Deal Equity Financing to Fund University Hospital Basel Collaboration

GlobeNewswire May 5, 2020

The Impressive Rise of Psychedelics Stocks

Omri Wallach May 4, 2020

Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips

Canada NewsWire April 21, 2020

MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations

Canada NewsWire April 20, 2020

REPEAT: MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

Canada NewsWire April 17, 2020

MindMed Announces U.S. Trading on the OTCQB Venture Market Under Symbol MMEDF

PR Newswire April 17, 2020

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

Canada NewsWire April 16, 2020

Bruce Linton’s New Psychedelic Play Debuts on the NEO Exchange

Stockhouse Editorial March 4, 2020

Broadway Gold Mining Ltd. Announces Shareholder and Court Approval and Closing Date of Previously Announced Plan of Arrangement With Mind Medicine, Inc.

GlobeNewswire February 24, 2020

Broadway Gold Mining Ltd. Provides Update to Proposed Arrangement With Mind Medicine, Inc.

GlobeNewswire January 24, 2020

Broadway Gold Mining Ltd. Announces Brokered Financing for MindMed

GlobeNewswire November 25, 2019

Mind Medicine, Inc. and Broadway Gold Mining Ltd. Announce Definitive Arrangement Agreement

GlobeNewswire October 15, 2019

Broadway Gold Mining Ltd. Announces Proposed Acquisition of Mind Medicine, Inc. and Related Financing Transactions

GlobeNewswire July 26, 2019

IIROC Trading Halt - BRD

Canada NewsWire July 5, 2019

Broadway Announces Commencement of Drilling at Madison

GlobeNewswire June 24, 2019

Broadway Acquires Copper/Vanadium Mining Camp in Namibia

GlobeNewswire June 3, 2019